Related Experiment Video

Updated: Jun 19, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

CDK10 is not a target for aberrant DNA methylation in breast cancer

Gerwin Heller1, Barbara Ziegler, Anita Brandstetter

  • 1Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

Anticancer Research
|October 23, 2009
PubMed
Abstract

Insights

Aberrant DNA methylation does not appear to be a mechanism driving tamoxifen resistance in breast cancer, as cyclin-dependent kinase (CDK) 10 was not found to be methylated in patient samples. CDK10 expression was consistently detected in all cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Loss of cyclin-dependent kinase (CDK) 10 expression is implicated in tamoxifen resistance.
  • The 5' CpG island of the CDK10 gene is a potential target for aberrant methylation in breast cancer.

Purpose of the Study:

  • To investigate the methylation status of CDK10 in breast cancer.
  • To determine if CDK10 methylation is associated with tamoxifen resistance.

Main Methods:

  • Methylation-specific PCR (MSP) was used to analyze the methylation status of CDK10, RASSF1A, and DAL-1 in 96 breast carcinoma FFPE specimens.
  • Reverse transcription kinetic PCR (RT-kPCR) assessed CDK10 expression.

Main Results:

  • CDK10, RASSF1A, and DAL-1 were unmethylated in all analyzed samples.
  • No methylation of the CDK10 5' region was detected in any of the 96 breast cancer samples.
  • RASSF1A and DAL-1 methylation were observed in 78% and 60% of samples, respectively, while CDK10 expression was detected in all samples.

Conclusions:

  • CDK10 is not a target for aberrant DNA methylation in breast cancer.
  • The findings suggest that other mechanisms, not CDK10 methylation, are responsible for tamoxifen resistance.

More Related Videos

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

Published on: September 26, 2019

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...